½ÃÀ庸°í¼­
»óǰÄÚµå
1741312

¼¼°èÀÇ Àν¶¸° °¨ÀÛÁ¦ ½ÃÀå : Àν¶¸° °¨ÀÛÁ¦ À¯Çüº°, ÀûÀÀÁõº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, Áö¿ªº°

Insulin Sensitizers Market, By Type of Insulin Sensitizers, By Indication, By Route of Administration, By Distribution Channel, By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Àν¶¸° °¨ÀÛÁ¦ ½ÃÀåÀº 2025³â¿¡´Â 237¾ï 7,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2032³â¿¡´Â 367¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³â±îÁöÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)Àº 6.4%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ ¼¼ºÎ Á¤º¸
±âÁØ ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 237¾ï 7,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
CAGR(2025-2032³â) 6.40% 2032³â ±Ý¾× ¿¹Ãø 367¾ï ´Þ·¯

Àν¶¸° °¨ÀÛÁ¦´Â Àν¶¸° °¨¼ö¼ºÀ» °³¼±Çϰí Ç÷´ç ¼öÄ¡¸¦ ³·Ãß´Â ¾à¹°ÀÔ´Ï´Ù. ÀÌ ¾à¹°Àº Ç÷´ç Á¶ÀýÁ¦ ¶Ç´Â À¯±Û¸®¼¼¹ÍÁ¦·Îµµ ¾Ë·ÁÁ® ÀÖÀ¸¸ç, Àν¶¸°À» »ç¿ëÇÏÁö ¾Ê°í Ç÷´çÀ» Á¤»ó ¹üÀ§·Î µÇµ¹¸®´Â µ¥ µµ¿òÀ» ÁÝ´Ï´Ù. ÀÌ ¾à¹°Àº °£, ±ÙÀ° ¹× Áö¹æ ¼¼Æ÷ÀÇ Àν¶¸° °¨¼ö¼ºÀ» Áõ°¡½ÃÄÑ ÀÛ¿ëÇÕ´Ï´Ù. Àν¶¸° °¨ÀÛÁ¦¿¡´Â ¸ÞÆ®Æ÷¸£¹Î(Met), ÇÇ¿À±Û¸®Å¸Á¸(Pio), Ƽ¾ÆÁ¹¸®µòµð¿Â(TZD), À̳ë½ÃÅç µîÀÌ ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

Àü ¼¼°è Àν¶¸° °¨ÀÛÁ¦ ½ÃÀå ¼ºÀåÀº ´ç´¢º´, ƯÈ÷ Á¦2Çü ´ç´¢º´ÀÇ À¯º´·ü Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Àν¶¸° °¨ÀÛÁ¦´Â Á¦2Çü ´ç´¢º´ Ä¡·á ½Ã Àν¶¸° °¨¼ö¼ºÀ» Çâ»ó½Ã۰í Ç÷´ç ¼öÄ¡¸¦ °ü¸®Çϱâ À§ÇØ ÀÚÁÖ »ç¿ëµË´Ï´Ù. 2Çü ´ç´¢º´°ú Àν¶¸° ÀúÇ×¼ºÀº ºñ¸¸À¸·Î ÀÎÇØ Å©°Ô Áõ°¡ÇÕ´Ï´Ù. È¿°úÀûÀÎ Àν¶¸° °¨ÀÛÁ¦´Â Àü ¼¼°èÀûÀ¸·Î Áõ°¡ÇÏ´Â ºñ¸¸ À¯º´·ü·Î ÀÎÇØ Àν¶¸° ÀúÇ×¼º°ú °ü·ÃµÈ ´ë»ç ÁúȯÀ» °ü¸®ÇÏ´Â µ¥ µµ¿òÀ» ÁÝ´Ï´Ù. Áö¼ÓÀûÀÎ ¿¬±¸ °³¹ß Ȱµ¿Àº »õ·Î¿î ¹× °³¼±µÈ Àν¶¸° °¨ÀÛÁ¦¸¦ µµÀÔÇÏ¿© Çõ½ÅÀûÀÎ È­ÇÕ¹°°ú Á¦Çü ¹æ¹ýÀ» °³¹ßÇϰí, Àν¶¸° °¨¼ö¼ºÀ» Ä¡·áÇÏ´Â ¾à¹°ÀÇ È¿´É°ú ¾ÈÀü¼º ÇÁ·ÎÇÊÀ» °³¼±Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Á¤ºÎ´Â ´ç´¢º´°úÀÇ ½Î¿òÀ» À§ÇØ ´Ù¾çÇÑ ÀÌ´Ï¼ÅÆ¼ºê¸¦ ½ÃÇàÇϰí ÀÖ½À´Ï´Ù. ÀÌ °èȹ°ú ÇÁ·Î±×·¥Àº ´ç´¢º´¿¡ ´ëÇÑ ÀÎ½Ä È®»ê, Á¶±â Áø´Ü, Àν¶¸° °¨ÀÛÁ¦¿Í °°Àº ÇʼöÀûÀ̰í Á¢±Ù °¡´ÉÇÑ Ä¡·á¹ý Á¦°ø¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù.

´Ù¸¥ ¾à¹°°ú ¸¶Âù°¡Áö·Î Àν¶¸° °¨ÀÛÁ¦´Â üÁß Áõ°¡, ü¾× Àú·ù, °ñÀý, ½ÉºÎÀü À§Çè Áõ°¡ µî ÀáÀçÀû ºÎÀÛ¿ëÀ» °¡Áú ¼ö ÀÖ½À´Ï´Ù. Ƽ¾ÆÁ¹¸®µòµð¿Â(TZD)°ú °°Àº ƯÁ¤ À¯ÇüÀÇ Àν¶¸° °¨ÀÛÁ¦´Â ¾ÈÀü¼º ¿ì·Á·Î ÀÎÇØ »ç¿ëÀÌ Á¦ÇÑµÇ°í ³Î¸® äÅõDZ⠾î·Á¿î °æ¿ì°¡ ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • º» º¸°í¼­¿¡¼­´Â ¼¼°èÀÇ Àν¶¸° °¨ÀÛÁ¦ ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2024³âÀ» ±âÁØ ¿¬µµÀ¸·Î ÇÑ ¿¹Ãø±â°£ 2025-2032³â ½ÃÀå ±Ô¸ð¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR%)À» Á¦°øÇÕ´Ï´Ù.
  • ¶Ç, ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀûÀÎ ¼öÀÍ ±âȸ¸¦ ¹àÇô, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¿¡ ´ëÇØ¼­ ÇØ¼³Çß½À´Ï´Ù.
  • ¶Ç ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¶Ç´Â ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ª¿¡ ÀÇÇÑ Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤ÅÃÇÏ´Â °æÀï Àü·« µî¿¡ °üÇÑ Áß¿äÇÑ °íÂûµµ Á¦°øÇÕ´Ï´Ù.
  • ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ½ÇÀû, Àü·« µîÀÇ ÆÄ¶ó¹ÌÅÍ¿¡ ±Ù°ÅÇØ, ¼¼°èÀÇ Àν¶¸° °¨ÀÛÁ¦ ½ÃÀå¿¡ À־ÀÇ ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏÀ» Á¦°øÇÕ´Ï´Ù.
  • º» º¸°í¼­·ÎºÎÅÍ ÅëÂû¿¡ ÀÇÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ³ª ±â¾÷ÀÇ °æ¿µÁøÀº Àå·¡ÀÇ Á¦Ç° ¹ß¸Å, Á¦Ç° ¾÷±×·¹À̵å, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ °üÇÑ Á¤º¸¿¡ ±Ù°ÅÇÑ ÀÇ»ç °áÁ¤À» ½Ç½ÃÇÒ ¼ö ÀÖ½À´Ï´Ù.
  • ¼¼°èÀÇ Àν¶¸° °¨ÀÛÁ¦ ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü°¡ÀÚ, À繫 ºÐ¼®°¡ µî ÀÌ »ê¾÷ÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î Çϰí ÀÖ½À´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚ´Â ¼¼°èÀÇ Àν¶¸° °¨ÀÛÁ¦ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤ÀÌ ¿ëÀÌÇØÁý´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ÀüÁ¦Á¶°Ç
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • º¸°í¼­ ¼³¸í
    • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à
  • ÀϰüµÈ ±âȸ Áöµµ(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
  • ´ç´¢º´ÀÇ À¯º´·ü Áõ°¡
  • ¼¼°èÀÇ ºñ¸¸ ¸¸¿¬ÀÇ È®´ë
  • ½Å¾à °³¹ßÀÇ ÁøÀü
  • Á¤ºÎÀÇ ±àÁ¤ÀûÀÎ Á¤Ã¥ Áö¿ø
    • ¾ïÁ¦¿äÀÎ
  • ºÎÀÛ¿ë°ú ¾ÈÀü¼º¿¡ ´ëÇÑ ¿ì·Á
  • ƯÁ¤ ȯÀÚ Áý´Ü¿¡¼­ÀÇ Á¦ÇÑµÈ È¿´É
  • ±ÔÁ¦ °úÁ¦ ¹× ½ÃÀå Á¢±Ù¼º
    • ±âȸ
  • ½ÅÈï ½ÃÀå
  • ¸ÂÃãÇü ÀÇ·á
  • °áÇÕ Ä¡·á¹ý
  • ´ç´¢º´ ÀÌ¿ÜÀÇ Àû¿ë ºÐ¾ß
  • ¿µÇ⠺м®
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • Á¦Ç° Ãâ½Ã ¹× ½ÂÀÎ
  • PEST ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • ÀμöÇÕº´(M&A) ½Ã³ª¸®¿À

Á¦4Àå ¼¼°èÀÇ Àν¶¸° °¨ÀÛÁ¦ ½ÃÀå : Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

  • COVID-19 ¿ªÇÐ
  • °ø±Þ Ãø¸é ¹× ¼ö¿ä Ãø¸é ºÐ¼®
  • °æÁ¦¿¡ ¹ÌÄ¡´Â ¿µÇâ

Á¦5Àå ¼¼°èÀÇ Àν¶¸° °¨ÀÛÁ¦ ½ÃÀå : Àν¶¸° °¨ÀÛÁ¦ À¯Çüº°(2020-2032³â)

  • ¼Ò°³
  • Ƽ¾ÆÁ¹¸®µòµð¿Â(TZD)
  • ºñ±¸¾Æ³ªÀ̵å
  • ÀÎÅ©·¹Æ¾ ±â¹Ý Ä¡·áÁ¦
  • ±âŸ

Á¦6Àå ¼¼°èÀÇ Àν¶¸° °¨ÀÛÁ¦ ½ÃÀå : ÀûÀÀÁõº°(2020-2032³â)

  • ¼Ò°³
  • Á¦2Çü ´ç´¢º´
  • Àü´ç´¢
  • ´Ù³¶¼º ³­¼Ò ÁõÈıº(PCOS)

Á¦7Àå ¼¼°èÀÇ Àν¶¸° °¨ÀÛÁ¦ ½ÃÀå : Åõ¿© °æ·Îº°(2020-2032³â)

  • ¼Ò°³
  • °æ±¸
  • ÁÖ»çÁ¦

Á¦8Àå ¼¼°èÀÇ Àν¶¸° °¨ÀÛÁ¦ ½ÃÀå : À¯Åë ä³Îº°(2020-2032³â)

  • ¼Ò°³
  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹

Á¦9Àå ¼¼°èÀÇ Àν¶¸° °¨ÀÛÁ¦ ½ÃÀå : Áö¿ªº°(2020-2032³â)

  • ¼Ò°³
  • ºÏ¹Ì
      • ¹Ì±¹
      • ij³ª´Ù
  • À¯·´
      • ¿µ±¹
      • µ¶ÀÏ
      • ÀÌÅ»¸®¾Æ
      • ÇÁ¶û½º
      • ½ºÆäÀÎ
      • ·¯½Ã¾Æ
      • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
      • Áß±¹
      • Àεµ
      • ÀϺ»
      • ASEAN ±¹°¡
      • È£ÁÖ
      • Çѱ¹
      • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
      • ºê¶óÁú
      • ¸ß½ÃÄÚ
      • ¾Æ¸£ÇîÆ¼³ª
      • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
      • GCC ±¹°¡
      • À̽º¶ó¿¤
      • ºÏ¾ÆÇÁ¸®Ä«
      • Áß¾Ó ¾ÆÇÁ¸®Ä«
      • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå °æÀï ±¸µµ

  • Eli Lilly and Company
  • Novo Nordisk
  • Sanofi
  • Merck & Co.
  • Bristol Myers Squibb
  • AstraZeneca
  • Boehringer Ingelheim
  • Johnson & Johnson
  • Takeda Pharmaceutical

Á¦11Àå ¼½¼Ç

  • Á¶»ç ¹æ¹ý
  • ȸ»ç ¼Ò°³
HBR 25.06.17

Insulin Sensitizers Market is estimated to be valued at USD 23.77 Bn in 2025 and is expected to reach USD 36.7 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.4% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 23.77 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 6.40% 2032 Value Projection: USD 36.7 Bn

Insulin sensitizers are medications that improve insulin sensitivity and reduce blood sugar levels. These are also known as blood sugar normalizing agents and euglycemics, and these help in returning blood glucose to the normal range without using insulin. These work by increasing liver, muscle and fat cells' sensitivity to insulin. There are several different types of insulin sensitizers including metformin (Met), pioglitazone (Pio), thiazolidinediones (TZDs), and inositols.

Market Dynamics

Global insulin sensitizers market growth is driven by increased prevalence of diabetes, especially type 2 diabetes. Insulin sensitizers are frequently used to increase insulin sensitivity and manage blood glucose levels in the treatment of type 2 diabetes. Type 2 diabetes and insulin resistance are both significantly increased by obesity. Effective insulin sensitizer helps in controlling insulin resistance and related metabolic diseases due to rising prevalence of obesity worldwide. The ongoing research and development activities have introduced new and enhanced insulin sensitizers that creates innovative compounds and formulation methods, and improves the efficacy and safety profiles of drugs that treat insulin sensitivity. Furthermore, the governments have taken several initiatives to combat diabetes. The plans and the programs focus on spreading knowledge about diabetes, early detection of diabetes and facilitating necessary and affordable treatments like insulin sensitizers.

Like any drugs, insulin sensitizers have potential side effects like weight gain, fluid retention, bone fractures, and an elevated risk of heart failure. Specific kinds of insulin sensitizers such as thiazolidinediones (TZDs) may create worries about its safety concern, thus, restricting their use and make them difficult to embrace widely.

Key features of the study:

  • This report provides in-depth analysis of the global insulin sensitizers market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global insulin sensitizers market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Eli Lilly and Company, Novo Nordisk, Sanofi, Merck & Co., Bristol Myers Squibb, AstraZeneca, Boehringer Ingelheim, Johnson & Johnson, Takeda Pharmaceutical
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global insulin sensitizers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global insulin sensitizers market

Insulin Sensitizers Market Detailed Segmentation:

  • By Type:
    • Thiazolidinediones (TZDs)
    • Biguanides
    • Incretin-based therapies
    • Others
  • By Indication:
    • Type 2 Diabetes
    • Prediabetes
    • Polycystic Ovary Syndrome (PCOS)
  • By Route of Administration:
    • Oral
    • Injectable
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region:
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
  • Company Profiles:
    • Eli Lilly and Company
    • Novo Nordisk
    • Sanofi
    • Merck & Co.
    • Bristol Myers Squibb
    • AstraZeneca
    • Boehringer Ingelheim
    • Johnson & Johnson
    • Takeda Pharmaceutical

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Insulin Sensitizers
    • Market Snippet, By Indication
    • Market Snippet, By Route of Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
  • Increasing prevalence of diabetes
  • Growing global obesity epidemic
  • Advancements in drug development
  • Favorable government initiatives
    • Restraints
  • Adverse effects and safety concerns
  • Limited efficacy in certain patient populations
  • Regulatory challenges and market access
    • Opportunities
  • Emerging economies
  • Personalized medicine
  • Combination therapies
  • Non-diabetic applications
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product Launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Insulin Sensitizers Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Insulin Sensitizers Market, By Type, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021-2032
    • Segment Trends
  • Thiazolidinediones (TZDs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
  • Biguanides
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
  • Incretin-based therapies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

6. Global Insulin Sensitizers Market, By Indication, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021-2032
    • Segment Trends
  • Type 2 Diabetes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn )
  • Prediabetes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Polycystic Ovary Syndrome (PCOS)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Global Insulin Sensitizers Market, By Route of Administration, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021-2032
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
  • Injectable
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

8. Global Insulin Sensitizers Market, By Distribution Channel, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021-2032
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

9. Global Insulin Sensitizers Market, By Region, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Region, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, For Region, 2021 -2032
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Insulin Sensitizers, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
      • U.S.
      • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Insulin Sensitizers, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Insulin Sensitizers, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Insulin Sensitizers, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Middle East & Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Insulin Sensitizers, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
      • GCC
      • Israel
      • North Africa
      • Central Africa
      • Rest of Middle East & Africa

10. Competitive Landscape

  • Eli Lilly and Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novo Nordisk
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Sanofi
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Merck & Co.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Bristol Myers Squibb
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • AstraZeneca
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Boehringer Ingelheim
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Johnson & Johnson
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Takeda Pharmaceutical
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Analyst Views

11. Section

  • Research Methodology
  • About us
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦